Home/Filings/4/0002001011-24-000089
4//SEC Filing

Reardon Andrew 4

Accession 0002001011-24-000089

CIK 0000886163other

Filed

Sep 24, 8:00 PM ET

Accepted

Sep 25, 8:54 PM ET

Size

8.1 KB

Accession

0002001011-24-000089

Insider Transaction Report

Form 4
Period: 2024-09-23
Reardon Andrew
CLO & Secretary
Transactions
  • Exercise/Conversion

    Common Stock

    2024-09-23$52.27/sh+2,000$104,54024,534 total
  • Sale

    Common Stock

    2024-09-23$99.60/sh2,000$199,20122,534 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2024-09-232,00070,944 total
    Exercise: $52.27Exp: 2032-08-01Common Stock (2,000 underlying)
Footnotes (1)
  • [F1]The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.

Issuer

LIGAND PHARMACEUTICALS INC

CIK 0000886163

Entity typeother

Related Parties

1
  • filerCIK 0001950232

Filing Metadata

Form type
4
Filed
Sep 24, 8:00 PM ET
Accepted
Sep 25, 8:54 PM ET
Size
8.1 KB